Our objective was to determine the effects of preshipping (PRE) vs arrival (ARR) medication with tilmicosin phosphate (MIC; Exp. 1 and 2) and feeding chlortetracycline (CTC; 22 mg/kg of BW from d 5 to 9; Exp. 2) on health and performance of beef calves received in the feedlot. Ninety-six steers (Exp. 1; pay weight 236 kg) and 240 (Exp. 2; average pay weight 188 kg) steer and bull calves were used. For Exp. 1, treatments included no MIC (CON), PRE, and ARR. For Exp. 2, treatments were arranged in a 3 × 2 factorial. Treatments included CON, PRE, and ARR, either with CTC or without CTC. For Exp. 2, serum concentrations of immunoglobulin (Ig)G and α-1-acid glycoprotein (AGP) were determined on samples collected on d 0, 5, 10, and 28 and d 0, 5, and 10, respectively. No MIC × CTC interactions were observed. No differences were
Introduction
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Received February 22, 1999 . Accepted August 17, 1999 267 noted among MIC or CTC treatments in any of the experiments for ADG, daily DMI, or gain:feed ratio for the overall receiving periods. For Exp. 1, percentage of steers treated for bovine respiratory disease (BRD) was decreased (P < .05) for MIC-treated animals vs CON (71.9, 45.2, and 46.9 for CON, PRE, and ARR, respectively), and the week that calves were treated for BRD differed (P < .10) among treatments. For Exp. 2, the number of calves treated for BRD was decreased (P < .01) for MIC-treated steers vs CON and decreased (P < .05) for ARR vs PRE (40.0, 18.7, and 7 .5% for CON, PRE, and ARR, respectively). Averaged across days, serum IgG was decreased (P < .05) for MIC-treated steers vs CON, with no differences noted among treatments for AGP. Results suggest that preshipping medication programs are no more effective than arrival medication programs using tilmicosin phosphate.
attributed to BRD. One management practice used to decrease the incidence and(or) severity of BRD is prophylactic medication. Previous research conducted at the Clayton Livestock Research Center (Galyean et al., 1995) concluded that tilmicosin phosphate (Micotil) offered a highly effective means of decreasing BRD in highly stressed beef cattle from the southeastern United States. Moreover, tilmicosin phosphate has been approved by the Federal Food and Drug Administration (FDA) for control of respiratory disease in cattle at high risk. It may be advantageous to administer antibiotics prior to shipping to obtain optimum health and performance. Feed-grade antibiotics may be an economical method to incorporate antibiotics into highly stressed animals. However, data are limited that evaluate effects of prophylactic medication with tilmicosin phosphate before shipping vs on arrival and effects and possible interactions with therapeutic concentrations of feed-grade chlortetracycline on health and performance. Our objective was to evaluate preshipping vs arrival medication with tilmicosin phos-phate and possible interactions with feed-grade chlortetracycline.
Experimental Procedures
Experiment 1. This experiment was initiated in December 1997. Ninety-five beef steers were purchased from an order buyer in Mississippi. Calves were purchased at an auction barn on a Monday and held at the order buyer's facility for preshipping processing for approximately 24 h. Thirty-one calves were randomly selected to receive a preshipping administration of tilmicosin phosphate (Elanco Anim. Health, Indianapolis, IN; 7.5 mL; PRE). Calves were shipped at 1530 (central time) on Tuesday and arrived at the Clayton Livestock Research Center at 1430 mountain time on Wednesday (1,648 km). Upon arrival, calves were weighed, branded, horn-tipped, vaccinated with a clostridial antigen (Ultrabac-7; SmithKline Beecham Animal Health, West Chester, PA), treated for internal (oxfendazole; Synanthic; Ft. Dodge Animal Health, Overland Park, KS) and external (fenthion; Tiguvon; Bayer Animal Health, Shawnee Mission, KS) parasites, and administered 2 mL of a vitamin A/D 3 solution containing 500,000 IU of vitamin A and 75,000 IU of vitamin D 3 /mL (AgriLabs, St. Joseph, MO), and 32 calves were administered tilmicosin phosphate (ARR). Within each of the treatment groups, calves were randomly assigned to pens (three pens per treatment with 10 to 11 calves per pen). After processing, steers were placed in their respective pens, offered sorghum-sudangrass hay (1st wk only) and a 70% concentrate diet (Table 1) in quantities sufficient for ad libitum consumption throughout the receiving period. On d 7, all cattle received an IBR-PI 3 -BVD-BRSV vaccine (Pyramid-4; Ft. Dodge Animal Health). Cattle were monitored daily for signs of BRD, including nasal or ocular discharge, labored breathing, lethargy, and(or) emaciated body condition. Cattle displaying symptoms were removed from their pens and rectal temperature was measured. Cattle with a rectal temperature > 39.7°C received medical treatments, which included tilmicosin phosphate (10 mg/kg BW) and 10 mL of penicillin. After medical treatments cattle were returned to their respective pens. After 48 h, cattle not responding to medical treatments were again pulled (repull) and treated with florfenicol (Nuflor; Schering-Plough Anim. Health Corp., Union, NJ) at 20 mg/kg BW if rectal temperature was > 39.7°C. Cattle were weighed (unshrunk) starting at 0730 on d 7, 21, and 35; any feed remaining in the feed bunk was weighed and sampled for DM determination on these days. Feed samples from random pens (300 g) were obtained at weekly intervals during the study and dried at 100°C for at least 22 h. Samples were analyzed for DM, ash, CP (AOAC, 1990) , and ADF (Goering and Van Soest, 1970) . Subsamples of the dietary ingredient samples were analyzed every 2 wk for DM determination. Performance data were analyzed using GLM procedures of SAS (1987) . Pen was considered the experimental unit. For ADG, the model included effects for tilmicosin phosphate treatment and pen within tilmicosin treatment. Tilmicosin phosphate treatment was tested using pen within tilmicosin phosphate as the error term. Pen means for DMI and gain:feed ratio were computed, and the model included effects for tilmicosin phosphate treatment. Orthogonal contrasts were used to separate tilmicosin phosphate treatment means. Contrasts were 1) control (CON; no tilmicosin) vs the average of PRE and ARR and 2) PRE vs ARR. Morbidity data were first analyzed using the CAT-MOD procedure of SAS (1987) with individual calves as the experimental unit. The model included effects for tilmicosin phosphate. Contrasts were used to separate tilmicosin phosphate treatment means for morbidity. Contrasts were 1) CON vs the average of PRE and ARR and 2) PRE vs ARR. Morbidity data were separated into 7-d periods to determine when steers were treated. The 7-d periods were then analyzed with chi-square procedures.
Experiment 2. Two loads of cattle were used in Exp. 2 during April 1998. Both loads contained 120 crossbred (British × Continental) beef bull and steer calves and were purchased from the same order buyer used in Exp. 1. Upon arrival, cattle were processed similarly to those in Exp. 1: they were weighed, branded, castrated, horn-tipped, vaccinated with a clostridial anti-gen (Fortress-7; Pfizer Animal Health; Exton, PA) and an IBR-PI 3 -BVD-BRSV vaccine (Bovishield-4; SmithKline Beecham Animal Health), treated for internal and external (Ivomec pour-on; Merial Animal Health, Rahway, NJ) parasites, and injected with 2 mL of a vitamin A/D 3 solution (AgriLabs). Treatments were arranged in a 3 × 2 factorial. Tilmicosin phosphate treatments included CON, PRE, and ARR. Chlortetracycline treatments included 1) no chlortetracycline (CTR) and 2) chlortetracycline fed on d 5 to 9 at 22 mg/kg of BW (as-fed basis; CTC). Chlortetracycline was provided in Aureomycin 10-g crumbles (22 g/kg; Farr Better Feeds, Hereford, TX). Aureomycin 10-g crumbles were made of processed grain by-products, roughage products (25%), forage products, molasses products, and calcium carbonate and had a guaranteed analysis of minimum CP 9.0%, minimum crude fat 2.5%, and maximum crude fiber 25%. Pens were assigned randomly to treatments (two pens per treatment per load with 10 calves per pen). Other procedures were identical to those in Exp. 1 during the 28-d receiving period. Cattle were weighed and bled via jugular venipuncture on d 0, 5, 10, 14, and 28. Serum was decanted and stored frozen for serum immunoglobulin G (IgG) and α-1-acid glycoprotein (AGP) analyses.
Serum IgG concentrations in samples collected on d 0, 5, 10, and 28 were quantified using a RIA procedure as described by Richards et al. (1999) with modifications for bovines. Rabbit antibovine IgG (product no. B-8395) and bovine IgG (product no. I-5506) were purchased from Sigma Chemical Co. (St. Louis, MO). Serum was diluted to 1:5,000 in PBS containing 1% BSA, and 25 µL was used in the RIA. Other buffer systems, iodination procedures, and assay protocols were similar to those reported by Richards et al. (1999) . Within-and between-assay CV were 14 and 13%, respectively.
Serum AGP was quantified in serum samples collected on d 0, 5, and 10 using a commercially available immunodiffusion assay kit (Bovine α 1 AG Plate; Code No. P0101; USDA Permit No. 862; CarioTech Services, Louisville, KY). A pooled serum sample with an AGP concentration of approximately 760 µg/mL from steers used in the current experiment was evaluated in triplicate with each assay of 100. The within-assay CV of pooled serum sample was 2.2%, and the betweenassay CV was 2.6%.
Performance data were analyzed using GLM procedures of SAS (1987) . Pen was considered the experimental unit. For ADG, the model included effects for tilmicosin phosphate, CTC treatment, tilmicosin phosphate × CTC, block (load), tilmicosin phosphate × block, CTC × block, tilmicosin phosphate × CTC × block, and pen within tilmicosin phosphate × CTC × block. Pen within tilmicosin phosphate × CTC × block was used to test effects for tilmicosin phosphate, CTC, and the tilmicosin phosphate × CTC interaction. Pen averages were computed with DMI and gain:feed analyzed with a model that included effects for tilmicosin phosphate treatment, CTC treatment, tilmicosin phosphate × CTC interaction, block (load), tilmicosin phosphate × block, CTC × block, and tilmicosin phosphate × CTC × block. Orthogonal contrasts were used to separate tilmicosin phosphate treatment means. Contrasts were 1) CON vs the average of PRE and ARR and 2) PRE vs ARR. Morbidity data were first analyzed using the CATMOD procedure of SAS (1987) with individual calves as the experimental unit. The model included effects for tilmicosin phosphate, CTC, and tilmicosin phosphate × CTC. Contrasts were used to separate tilmicosin phosphate treatment means for morbidity. Contrasts were 1) CON vs the average of PRE and ARR and 2) PRE vs ARR. No tilmicosin phosphate × CTC interactions were observed; therefore, chi-square analysis was used to analyze morbidity data for Aureomycin (AUR) treatments. Morbidity data were separated into 5-d periods to determine when steers were treated. The 5-d periods were then analyzed with chi-square procedures. Only six steers required more than one treatment (repull) for BRD; therefore, repull data were not analyzed. Serum concentrations of IgG and AGP were analyzed as split-plot analyses of variance for repeated measures (Gill and Hafs, 1971) . The model included tilmicosin phosphate treatment, CTC, and tilmicosin phosphate × CTC in the main plot and day, tilmicosin phosphate × day, CTC × day, and tilmicosin phosphate × CTC × day in the subplot. Tilmicosin phosphate, CTC, and tilmicosin phosphate × CTC were tested using pen within tilmicosin phosphate × CTC as the error term, and subplot effects were tested using residual error.
Results
Experiment 1. Cattle experienced 5.2% shrinkage from a pay weight of 236 kg and 35.7% required horntipping. No differences (P > .10) were noted among treatments for daily gain for any of the periods or the overall experiment (Table 2) . Daily DM intake of concentrate (P < .10) and total DM intake (P < .05) were greater during d 0 to 7 and greater (P < .05) for d 7 to 21 for calves receiving tilmicosin phosphate treatments compared with controls. However, no differences (P > .10) were noted for DM intake during d 21 to 35 or for d 0 to 35. Likewise, no differences were detected (P > .10) for the gain:feed ratio for any of the periods or for the overall experiment among treatments. The percentage of steers treated for BRD was decreased (P < .05) in tilmicosin phosphate-treated groups compared with controls. Likewise, chi-square analysis revealed that the week the steers were treated for BRD differed (P < .10) among treatments (Table 3 ). No differences (P > .10) were noted for the number of cattle treated more than once for BRD.
Experiment 2. Cattle experienced 6.3 and 5.7%
shrinkage from pay weights of 187 and 190 kg (Load Control = no tilmicosin phosphate; preshipping = preshipping medication with tilmicosin phosphate (7.5 mL); arrival = arrival medication with tilmicosin phosphate (7.5 mL). 1 and 2, respectively), 80 and 73.3% were castrated (Load 1 and 2, respectively), and horn-tipping was required for 26.7 and 27.5% of the calves (Load 1 and 2, respectively). A tilmicosin phosphate × chlortetracycline treatment interaction (P < .05) was observed during days 5 to 10 of the experiment. For d 5 to 10, Control = no tilmicosin phosphate; preshipping = preshipping medication with tilmicosin phosphate (7.5 mL); arrival = arrival medication with tilmicosin phosphate (7.5 mL). the CON group responded to AUR in the diet with greater improvement in ADG compared with PRE and ARR (−.18, −.58, .40, −1.14, .07, and −.38 for ARR:AUR, ARR:CTR, CON:AUR, CON:CTR, PRE:AUR, and PRE:CTR, respectively). No other interactions were observed. Average daily gain was improved (P < .10) Within a row for chlortetracycline treatments, means lacking a common superscript letter differ (P < .10).
for the average of the tilmicosin phosphate treatments vs controls and for ARR vs PRE (P < .10) during d 0 to 5 (Table 4) . Likewise, average daily gain was improved for the average of the tilmicosin phosphate treatments vs control cattle on d 10 to 14 (P < .05) and 0 to 14 (P < .01) of the experiment. No other differences were noted among treatments for daily gain. Cattle receiving CTC gained .05 kg per animal during d 5 to 10, whereas control cattle lost .32 kg per animal during the same period (P < .01). Control cattle compensated for the decreased gain during d 5 to 10 and had greater ADG during d 10 to 14 than cattle receiving CTC (P < .10). No other differences in ADG were observed for CTC treatments. Daily DM intake did not differ among tilmicosin phosphate or CTC treatments during either of the 14-d periods or for the overall 28-d receiving period (Table 4) . Gain:feed ratio was increased for tilmicosin phosphate vs control (P < .01) and for arrival vs preshipping (P < .10) treatments during d 0 to 14 of the experiment. Likewise, gain:feed was increased with vs without chlortetracycline (P < .10) during d 0 to 14. No other differences in the gain:feed ratio were observed for either tilmicosin phosphate or chlortetracycline treatments. The percentage of steers treated for BRD was decreased (P < .01) for the average of the tilmicosin phosphate treatments compared with controls and decreased (P < .05) for ARR vs PRE (Table 5) . No differences were observed for CTC treatments for the percentage of calves treated for BRD. No differences were observed for tilmicosin phosphate or CTC treatments in the period that cattle were treated for BRD.
Averaged across sampling days, total IgG concentrations were decreased (P < .05) for the average of tilmicosin treatments vs untreated controls (Table 6 ). No differences were noted for total IgG concentrations between CTC treatments. The AGP concentrations did not differ (P > .10) among tilmicosin treatments or CTC treatment averaged across sampling days.
Discussion
Results from these experiments evaluating effects of tilmicosin treatments on performance during the receiving period are in general agreement with other reported research. Galyean et al. (1995) also noted no No tilmicosin phosphate × chlortetracycline interactions (P > .10) were observed.
b CON = no tilmicosin phosphate; PRE = preshipping medication with tilmicosin phosphate (6.0 mL); ARR = arrival medication with tilmicosin phosphate (6.0 mL). Chlortetracycline fed at either 0 (without) or 22 mg/kg of BW for 5 d (with). difference in ADG in two of three studies evaluating effects of tilmicosin phosphate on health and performance by newly received beef calves. In the third study by Galyean et al. (1995) , tilmicosin phosphate treatment en masse or based on rectal temperature increased ADG during an initial 28-d receiving period and a subsequent 28-d feeding period. Other research supports increased ADG when cattle received tilmicosin treatments at processing (McCoy et al., 1994; Brazle, 1997; Klemesrud et al., 1997; Vogel et al., 1998) .
We noted an increase in feed intake during Exp. 1 early in the receiving period and an improved feed efficiency early in the receiving period during Exp. 2 with tilmicosin phosphate treatments vs controls. However, for the overall receiving period, no differences were noted for DMI or gain:feed with tilmicosin treatments. Other research has noted improved DMI and feed efficiency with tilmicosin treatments (Galy- Split-plot analysis of variance revealed no tilmicosin phosphate × chlortetracycline, tilmicosin phosphate × day, chlortetracycline × day, or tilmicosin phosphate × chlortetracycline × day interactions (P > .10). Therefore, tilmicosin phosphate and chlortetracycline means were averaged across sampling days. b CON = no tilmicosin phosphate; PRE = preshipping medication with tilmicosin phosphate (6.0 mL); ARR = arrival medication with tilmicosin phosphate (6.0 mL). Chlortetracycline fed at either 0 (without) or 22 mg/kg of BW for 5 d (with).
c Observed significance level of contrasts: 1 = control vs medication; 2 = preshipment vs arrival medication. NS = not statistically significant. ean et al., 1995; Klemesrud et al., 1997; Vogel et al., 1998) ; however, responses have varied in some studies (Galyean et al., 1995) . Effects of tilmicosin phosphate treatments on DMI and feed efficiency most likely relate to the incidence of morbidity, because morbid calves eat less feed than nonmorbid animals.
Our objective was to evaluate effects of tilmicosin phosphate administered either preshipping or on arrival. No other published research has evaluated mass medication treatments using tilmicosin phosphate before shipping vs on arrival. If the cattle succumb to agents they are not previously exposed to at auction barns, it should be advantageous to give the tilmicosin phosphate before shipping. The only differences that we noted between preshipping vs arrival medication with tilmicosin phosphate were an increased total DMI for preshipping vs arrival medication during the first 7 d for Exp. 1 and increased ADG for arrival medication vs preshipping during the first 5 d for Exp.
2. These studies further demonstrate that effects of medication treatments may be dependent on time of year that cattle are purchased and the subsequent percentage morbidity observed. Previous studies evaluating synchronizing tilmicosin treatments reported no differences in performance when tilmicosin was administered at arrival or 72 h later (Schumann et al., 1991) or mass treatment on d 0 or 6 (Klemesrud et al., 1997) .
A consistent response in all three of our studies was a decreased percentage of calves treated for BRD with tilmicosin treatments vs controls. This suggests that tilmicosin phosphate continues to be an effective antibiotic in prevention of respiratory disease. The same responses have been noted both earlier (Schumann et al., 1991; Morck et al., 1993) and later (Vogel et al., 1998) in the decade, suggesting that tilmicosin phosphate is not losing effectiveness. We noted decreased percentage of calves treated for respiratory disease when tilmicosin phosphate was administered on arrival vs preshipping during Exp. 2, but no differences were noted during Exp. 1. Other reports have noted no difference for the percentage of morbid calves when tilmicosin phosphate was administered at arrival or 3 d later (Schumann et al., 1991) or at arrival and 6 d later (Klemesrud et al., 1997) . Morbidity during Exp. 2 seemed to be less than morbidity during Exp. 1. Therefore, timing of mass medication with tilmicosin phosphate may be dependent on the severity of an outbreak of BRD and(or) the severity is a function of when animals are exposed to the causative agents.
Results from Exp. 1 suggest an advantage to administering tilmicosin phosphate before shipping on the percentage of cattle treated for BRD during the 1st wk after arrival. Likewise, numerically, the percentage of cattle requiring more than one treatment was decreased for tilmicosin phosphate-treated steers compared with controls. Based on results of Exp. 1, we conducted Exp. 2 to determine effects and possible interactions of feed-grade antibiotics in addition to an injection on health and performance of newly received beef cattle.
Although widely used by the feedlot industry, limited published research is available evaluating effects of CTC on health and performance of newly received calves. Cole (1996) reported that when morbidity and mortality is low, use of antibiotics in the receiving diet has produced good results. With higher levels of morbidity, calves may not consume enough of the antibiotic (Cole, 1996) . Results from Exp. 2 suggest that when CTC is offered to the calves, animals receiving the product maintained their BW, whereas steers not receiving CTC lost BW. Likewise, feed efficiency was increased for the first 14 d of the receiving period. Although not statistically significant, the percentage of calves treated for BRD was less for animals receiving CTC vs controls. Anecdotal information suggests that when therapeutic levels of antibiotics are fed, ruminal fermentation and diet digestibility may be reduced. However, Zinn (1992) reported that in Holstein steers fed 71% concentrate diets, antibiotic supplementation may slightly lower the DE value of the diet, but effects on diet ME were small because of decreased energy loss as methane. In addition, no treatment effect on ruminal pH was noted, and molar proportion of acetate was lower and of propionate was higher for antibiotic-supplemented diets (Zinn, 1992) . In addition, Zinn (1986) reported that short-term feeding of antibiotics did not affect the nutritive value of growing and finishing diets.
Steers in Exp. 2 were also bled, and serum was analyzed for total concentrations of IgG. The lower concentrations of total IgG for the average of tilmicosin phosphate vs controls and numerically lower total IgG for CTC suggest that both injectable and feed-grade antibiotics decrease the elements responsible for mounting an immune response. Serum AGP was analyzed in serum samples collected on d 0, 5, and 10 of the receiving period in an attempt to further elucidate effects of antibiotics on animal health. Serum AGP has been implicated to increase with an increased susceptibility of infection and a suppression of lymphocyte blastogenesis in mastitic cows (Sato et al., 1995) . Lack of an effect of tilmicosin phosphate and CTC treatments on serum AGP, given differences in morbidity, suggest that serum AGP concentrations may not fully indicate the animal's susceptibility to infection.
Implications
When the percentage of cattle treated for bovine respiratory disease is low, the optimum time to administer medications en masse is at arrival. Feeding chlortetracycline resulted in greater average daily gain during the time that it was fed. Feeding chlortetracycline at a time close to an outbreak may prove advantageous.
